Active, not recruiting
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
NCT07166419
- Conditions
- Blast Crisis, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Bone Marrow Diseases, +39 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States